Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Dose Escalation|Safety|Preliminary Efficacy|Advanced Solid Tumors|Metastatic Breast Cancer|Advanced Pancreatic Adenocarcinoma|Metastatic Colorectal Cancer|Recurrent Glioblastoma Multiforme|Gastric Cancer|Gastroesophageal Junction Cancer|Triple Negative Metastatic Breast Cancer|Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions: DRUG: LDE225|DRUG: BKM120
Sponsor: Novartis Pharmaceuticals